TB 402

04/01/2012 - "The antithrombotic efficacy of TB-402 and BO2C11 was compared in a mouse model of venous thrombosis. "
04/01/2012 - "In a mouse model of FeCl(3)-induced venous thrombosis, TB-402 (1mg/kg) inhibited thrombus formation to the same extent as BO2C11 (2mg/kg) and enoxaparin (5mg/kg), with a mean (±SD) occlusion time of 51 ± 13 minutes for TB-402, compared to 28 ± 6 minutes for the controls, 51 ± 13 minutes for BO2C11 and 55 ± 11 minutes for enoxaparin. "

06/01/2010 - "AEs were monitored up to the last study visit on day 56 after the administration of TB-402 or placebo, with special attention to bleeding events. "
06/01/2010 - "No serious AEs considered to be related to TB-402 were reported, and no dose-dependent increases in bleeding events were observed. "
06/01/2010 - "A total of 34 bleeding events were reported in 13 of 38 subjects (34%) who received TB-402 and 7 of 18 subjects (39%) who received placebo. "
06/01/2013 - "The incidence of major and clinically relevant non-major bleeding was higher in the TB-402 groups than in the rivaroxaban group."
04/01/2011 - "The incidence of major and clinically relevant non-major bleeding was similar to enoxaparin 40 mg for TB-402 0.3 and 0.6 mg kg(-1)."

06/01/2013 - "TB-402 for the prevention of venous thromboembolism in orthopaedic surgery: something new and promising, or not?"
04/01/2011 - "We evaluated the efficacy and safety of a single administration of TB-402 for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR). "
04/01/2011 - "Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial."
06/01/2013 - "Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. "
06/01/2013 - "TB-402 is a long-acting monoclonal antibody that partially inhibits factor VIII. A single administration of TB-402 was effective and well-tolerated for the prevention of venous thromboembolism (VTE) after total knee replacement. "

04/01/2012 - "In a mouse model of FeCl(3)-induced venous thrombosis, TB-402 (1mg/kg) inhibited thrombus formation to the same extent as BO2C11 (2mg/kg) and enoxaparin (5mg/kg), with a mean (±SD) occlusion time of 51 ± 13 minutes for TB-402, compared to 28 ± 6 minutes for the controls, 51 ± 13 minutes for BO2C11 and 55 ± 11 minutes for enoxaparin. "

06/01/2010 - "Most common AEs reported in subjects who received TB-402 were headache (11 [29%]), vessel puncture-site hematoma (7 [18%]), and traumatic hematoma (5 [13%]); with placebo, these AEs were vessel puncture-site hematoma (4 [22%]), headache (3 [17%]), vasovagal reaction (3 [17%]), and hematuria (3 [17%]). "